Clinical trial
Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major…
NCT00320632 · Harvard Medical School (HMS and HSDM), Other · Completed
Key facts
| NCT number | NCT00320632 |
|---|---|
| Title | Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression |
| Official title | Psychopharmacology of Biogenic Amines in Depression |
| Lead sponsor | Harvard Medical School (HMS and HSDM), Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Desipramine |
| Enrollment | 43 |
| Start date | Aug 1, 1990 |
| Completion | Jul 1, 1993 |
| First posted | May 3, 2006 |
| Last update posted | Aug 19, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: